Detalles de la búsqueda
1.
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
BMC Infect Dis
; 17(1): 420, 2017 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28610605
2.
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
Hepatology
; 59(6): 2152-60, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24449403
3.
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Gastroenterology
; 145(4): 790-800.e3, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23811112
4.
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.
J Hepatol
; 58(3): 467-72, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23183524
5.
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
Hepatology
; 53(4): 1109-17, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21480317
6.
Hepatitis C treatment outcomes in Australian clinics.
Med J Aust
; 196(10): 633-7, 2012 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-22676878
7.
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
J Hepatol
; 53(4): 616-23, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20619475
8.
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.
Hepatology
; 50(4): 1045-55, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19676125
9.
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Int J Drug Policy
; 47: 230-238, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28633998
10.
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Int J Drug Policy
; 47: 177-186, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28624134
11.
Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.
Addiction
; 111(2): 311-9, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26451534
12.
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.
Expert Opin Drug Saf
; 11(6): 901-9, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22943161
13.
Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.
Addiction
; 106(5): 977-84, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21205057
14.
Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
Antivir Ther
; 16(2): 173-80, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21447866
15.
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Nat Genet
; 41(10): 1100-4, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19749758
Resultados
1 -
15
de 15
1
Próxima >
>>